Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (October 2024)
19 slides from Microbot Medical's investor presentation, Oct 31, 2024
Slide 1: Redefining Surgical Robotics
microbet fo * ( ibereyy micrabot medical y = = ENDOVASCULAR ROBOTIC SYSTEM yf = | Redefining Surgical Robotics
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating t
Slide 3: Microbot At-a-Glance
Microbot At-a-Glance (@) Large and (@) Significant Differentiated ») First Mover (©) Emergent Market (@Y) Unmet Needs Robotic Solution ) Advantage + Many endovascular procedures are Ne + Difficulty navigating complex LIBERTY? is the world's 1* fully + No commercially available robotic anatomy dispos
Slide 4: Large and Emergent Market
Large and Emergent Market @ >6 million annual endovascular procedures performed US Market Endovascular in the US (15 million worldwide) Procedures Performed Annually @ >$40B spent annually in the US Neurovascular Procedures @ Performed by 15,000 physicians — 9,000 interventional cardiologists — 3,00
Slide 5: Initial Target Market: Peripheral Vascular
Initial Target Market: Peripheral Vascular micropot INITIAL TARGET : ANNUAL : TARGET PROCEDURES (USA): : SPENDING(USA): : PHYSICIANS (USA): 23M $15B — 6,000 Peripheral Vascular 5 Procedures AVG. ANNUAL # OF : FACILITIES PERFORMING PROCEDURES PER : PROCEDURES (USA): PHYSICIAN (USA): : 2,200 Hospitals
Slide 6: Significant Unmet Needs
@ Significant Unmet Needs medical Endovascular procedures are ripe for disruptive innovation that can improve procedure efficiency, HCP health & safety, while enabling access to quality care for both providers and patients Procedure Efficiency ® Managing catheter and guidewire exchanges requires mul
Slide 7: Differentiated Robotic Solution
Differentiated Robotic Solution microbot The LIBERTY® Endovascular Robotic System is disruptive technology designed to change the standard of care for endovascular procedures Single-use, fully-disposable without need for capital investment Empowers physicians to precisely steer guidewires and cathet
Slide 8: Slide 8
Slide 9: The LIBERTY Value Proposition
medical @ Differentiated Robotic Solution The LIBERTY® Value Proposition Improve Access to Robo Improved Lower improve Improve Increase Patient and Reduce Complexity Safety Costs Efficiency Care to Care UNMET NEED: Conventional | UNMET NEED: Dus to UNMET NEED: Manual UNMET NEED: Wire UNMET NEED: Les
Slide 10: Differentiated Robotic Solution: intellectual property portfolio
@ Differentiated Robotic Solution microbot LIBERTY® is protected by a strong intellectual property portfolio that includes patents and trademarks ‘ 7 trademarks ee registered Worldwide ° patent applications pending worldwide patents issued/allowed Worldwide
Slide 11: First Mover Advantage
First Mover Advantage microbot LIBERTY® was designed to eliminate barriers and enable adoption of robotics in endovascular procedures Barriers to Adoption Other Robotic Systems Cost of acquisition Y Large capital investment / Single-u \ e with no in Y Disposable procedure kit f v Annual service agre
Slide 12: First Mover Advantage
@ First Mover Advantage There is currently no commercially robotic system available in the US for endovascular procedures Several companies are developing robotic solutions due to the attractive market and untapped potential Microbot is uniquely positioned for success with our unique design and firs
Slide 13: Attractive Reimbursement
@ Attractive Reimbursement icrobot Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY® Y90 for Part 1 — Mapping procedure Dx Angiogram (75726) $43,990.21 Liver Cancer Part 2 —- Embolization procedure Coil placement (37242)
Slide 14: Unique Business Model
© Unique Business Model The fully disposable feature of LIBERTY offers an attractive business model to position LIBERTY for commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders Continuous Consumable Ci Infr: No Custom Infrastructure Revenue No
Slide 15: Clear Path to Commercialization
© Clear Path to Commercialization icrObot With the recent and successful completion of many major milestones, LIBERTY® has a clear path to U.S. launch in Q2 2025 Be a 9 ay Completed Received Submitting FDA IDE ISO 13486 Biocompatibility IDE 510(k) application Clearance Submission Certification Tests
Slide 16: Experienced Team
@ Experienced Team Leadership Team a a Harel Gadot CEO, President & Chairman M. Gadot is a seasoned executive land entrepreneur in the healthcare space, with an extensive and proven track record of leadership positions in the corporate world as well as the start-up sector, including the United State
Slide 17: Experienced Team: Board of Directors
@ Experienced Team icrobot Board of Directors S. ; a Harel Gadot Martin J. Madden Tal Wenderow Scott Burell, CPA CEO, President & Chairman Director Director Director Linkedin Linkedin Linkedin Linkedin aT a Aileen Stockburger P. Laxminarain Yossi Bornstein Director Director Director Linkedin Linkedi
Slide 18: Summary
Summary microbot LIBERTY? is a differentiated solution in a large and emergent market, with clear unmet needs and attractive reimbursement In the U.S., endovascular procedures historically have high reimbursement, with capacity for integrating new technologies like robotics that is expected to add v
Slide 19: Microbot Medical contact
microbot medical Harel Gadot CEO, President & Chairman O: #1 781-875-3605 M: +1 908 938 5561 E: harel@microbotmedical.com NASDAQ CM: MBOT liberty liberk& Mmicrobot medical W
Microbot Medical — Investor Presentation (October 2024) on 6ix